October 24, 2023 | 1:00 PM - 5:00 PM ET
A thorough understanding of Hatch-Waxman and the BPCIA is essential to anyone working in the biopharmaceutical area. This series, presenting virtually on our new state of the art interactive platform, will provide an in-depth review of Hatch-Waxman and the BPCIA as well as other IP basics relative to small molecules and biologics. This program will lay the necessary foundation to understand the dynamics of the applicable patent life cycles for biopharmaceutical products and business development plans.
Brian Burgess will speak during week 3's module, "Focus on Bioequivalence, Exclusivity, Extensions, and Exceptions."